Juliana de Moura

Dr. Juliana de Moura

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2007 in Molecular Endocrinology
Verified
Journal Article
Closed access
MDMabrouka Doghman
Mabrouka Doghman
TKTatiana S Karpova
Tatiana S Karpova
GRGiovanna Assis Rodrigues
Giovanna Assis Rodrigues
MAMalika Arhatte
Malika Arhatte
JMJuliana de Moura
Juliana de Moura
Enzo LalliEnzo Lalli
Enzo Lalli
Steroidogenic factor-1 (SF-1/Ad4BP; NR5A1), a nuclear receptor transcription factor, has a pivotal role in adrenal and gonadal development in humans and mice. A frequent feature of childhood adrenocortical tumors is SF-1 amplification and overexpression. Here we show that an increased SF-1 dosage can by itself augment human adrenocortical cell proliferation through concerted actions on the cell cycle and apoptosis. This effect is dependent on an intact SF-1 transcriptional activity. Gene expression profiling showed that an increased SF-1 dosage regulates transcripts involved in steroid metabolism, the cell cycle, apoptosis, and cell adhesion to the extracellular matrix. Consistent with these results, increased SF-1 levels selectively modulate the steroid secretion profile of adrenocortical cells, reducing cortisol and aldosterone production and maintaining dehydroepiandrosterone sulfate secretion. As a model to understand the mechanisms of transcriptional regulation by increased SF-1 dosage, we studied FATE1, coding for a cancer-testis antigen implicated in the control of cell proliferation. Increased SF-1 levels increase its binding to a consensus site in FATE1 promoter and stimulate its activity through modulation of the recruitment of specific cofactors. On the other hand, sphingosine, which can compete with phospholipids for binding to SF-1, had no effect on the SF-1 dosage-dependent increase of adrenocortical cell proliferation and expression of the FATE1 promoter. In mice, increased Sf-1 dosage produces adrenocortical hyperplasia and formation of tumors expressing gonadal markers (Amh, Gata-4), which originate from the subcapsular region of the adrenal cortex. Gene expression profiling revealed that genes involved in cell adhesion and the immune response and transcription factor signal transducer and activator of transcription-3 (Stat3) are differentially expressed in Sf-1 transgenic mouse adrenals compared with wild-type adrenals. Our studies reveal a critical role for SF-1 dosage in adrenocortical tumorigenesis and constitute a rationale for the development of drugs targeting SF-1 transcriptional activity for adrenocortical tumor therapy.

1 December 2007 in Toxicon
Verified
Journal Article
Closed access
EKEvanguedes Kalapothakis
Evanguedes Kalapothakis
MCM. Chatzaki
M. Chatzaki
HGH. Gonçalves-Dornelas
H. Gonçalves-Dornelas
CCC.S. de Castro
C.S. de Castro
FSF.G. Silvestre
F.G. Silvestre
KBK.C. Barbaro
K.C. Barbaro

1 August 2007 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
MDMabrouka Doghman
Mabrouka Doghman
MAMalika Arhatte
Malika Arhatte
HTHélène Thibout
Hélène Thibout
GRGiovanna Rodrigues
Giovanna Rodrigues
JMJuliana de Moura
Juliana de Moura
Enzo LalliEnzo Lalli
Enzo Lalli
Context: Childhood adrenocortical tumors (ACTs) have a fetal adrenal phenotype and overexpress steroidogenic factor-1 (SF-1). Nephroblastoma overexpressed (NOV)/cysteine-rich protein 61/connective tissue growth factor/nephroblastoma overexpressed gene-3 mRNA is significantly down-regulated in childhood ACTs. Objective: The objective of the study was to measure NOV protein levels in childhood ACTs and characterize NOV expression regulation and biological function in human adrenocortical cells. Design and Setting: Protein extracts from ACT and normal adrenal cortex samples, human adrenocortical carcinoma H295R, primary adrenocortical tumors and fetal adrenal cultures, tissue culture supernatants, and cell lysates from H295R cells overexpressing SF-1 in an inducible fashion were used. Main Outcome Measures: NOV protein levels were measured by enzyme-linked immunoassay and immunoblot. Transient transfection assays were used to study the activity of NOV promoter. Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling, caspase assays, and flow cytometry were used to assess the proapoptotic activity of NOV on cells in culture. Results: NOV mRNA and protein expression is lower in childhood ACTs than in normal adrenal cortex. No significant difference was observed between adenomas and carcinomas. SF-1 overexpression down-regulates NOV at the transcriptional level. NOV has a selective proapoptotic activity toward human adrenocortical cells. The C-terminal domain of NOV is responsible for its proapoptotic effect. NOV protein is expressed in DAX-1-positive human fetal adrenal cells. Conclusions: NOV is a selective proapoptotic factor for human adrenocortical cells. Reduced expression of NOV in ACTs may play an important role in the process of childhood ACT tumorigenesis, accounting at least in part for the defect of apoptotic regression of the fetal adrenal that has been proposed to be responsible for tumor formation.

19 May 2009 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
DCDaniele Chaves-Moreira
Daniele Chaves-Moreira
OCOlga Meiri Chaim
Olga Meiri Chaim
YSYoussef Sade
Youssef Sade
KPKátia S. Paludo
Kátia S. Paludo
LGLuiza Gremski
Luiza Gremski
SVSilvio Veiga
Silvio Veiga

1 December 2007 in Toxicon
Verified
Journal Article
Closed access
RRRodrigo Otávio S. Ribeiro
Rodrigo Otávio S. Ribeiro
OCOlga Meiri Chaim
Olga Meiri Chaim
RSRafael Bertoni da Silveira
Rafael Bertoni da Silveira
LGLuiza Gremski
Luiza Gremski
YSYoussef Sade
Youssef Sade
SVSilvio Veiga
Silvio Veiga

1 December 2003 in Toxicon
Verified
Journal Article
Closed access
LALarissa Alvarenga
Larissa Alvarenga
MMMaria S Martins
Maria S Martins
JMJuliana de Moura
Juliana de Moura
EKEvanguedes Kalapothakis
Evanguedes Kalapothakis
JOJúlio C Oliveira
Júlio C Oliveira
CCCarlos Chávez-Olórtegui
Carlos Chávez-Olórtegui